close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

867.94 +23.44 (+2.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday ↗
Wells Fargo raised the price target for Royal Caribbean Cruises Ltd. (NYSE: RCL) from $78 to $88. Wells Fargo analyst Daniel Politzer maintained an Overweight rating. Royal Caribbean Cruises shares... 
Via Benzinga
News headline image
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at BofA Securities 2023 Health Care Conference
From argenx SE
Via GlobeNewswire
News headline image
Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
A Bearish Sign Appears On argenx's Chart ↗
 
Via Benzinga
News headline image
Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment ↗
 
Via Benzinga
News headline image
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
From argenx SE
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023 ↗
 
Via Benzinga
News headline image
7 Biotech Stocks That Could Cure Your Portfolio Woes ↗
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
News headline image
5 Analysts Have This to Say About argenx ↗
 
Via Benzinga
News headline image
Earnings Outlook For argenx ↗
 
Via Benzinga
Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
From argenx SE
Via GlobeNewswire
News headline image
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
From argenx SE
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Planned Transition of Chief Operating Officer
From argenx SE
Via GlobeNewswire
News headline image
argenx Appoints Steve Krognes to Board of Directors
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
From argenx SE
Via GlobeNewswire
News headline image
Immunovant Could Potentially Be An M&A Target, Writes Analyst ↗
 
Via Benzinga
News headline image
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
News headline image
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
From argenx SE
Via GlobeNewswire
News headline image
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in... 
Via Benzinga
News headline image
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
From argenx SE
Via GlobeNewswire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.